Perioperative Treatment of Sunvozertinib in Stage II-IIIB NSCLC
This is a single-arm, phase 2 study to investigate the efficacy and safety of sunvozertinib as neoadjuvant and adjuvant treatment for stage II-IIIB non-small-cell lung cancer patients with EGFR exon20 insertion mutation.
NSCLC
DRUG: Sunvozertinib
Objective response rate (ORR) of neoadjuvant therapy, Complete response (CR) or partial response (PR) per investigator assessment according to RECIST 1.1, From enrollment to the end of neoadjuvant therapy at 12 weeks
Major pathological response (MPR), Pathological detection within 1month after surgery|Pathological complete response (pCR), Pathological detection within 1 month after surgery|Downstaging rate of N2 lymph nodes, From enrollment to the end of neoadjuvant therapy at 12 weeks|Disease control rate (DCR) of neoadjuvant therapy, From enrollment to the end of neoadjuvant therapy at 12 weeks|Event free survival (EFS), From date of enrollment until the date of first documented disease progression, relapse, or death due to any cause progression, whichever came first, assessed up to 60 months|Disease free survival (DFS), From date of surgical resection until the date of first documented disease relapse or death due to any cause , whichever came first, assessed up to 56 months|Overall survival (OS), From date of enrollment until the date of death due to any cause , assessed up to 84 months|Adverse events, From date of enrollment until the end of the study, assessed up to 36 months
This is a single-arm, phase 2 study to investigate the efficacy and safety of sunvozertinib as neoadjuvant and adjuvant treatment for stage II-IIIB non-small-cell lung cancer patients with EGFR exon20 insertion mutation.